PMC:7105881 / 1419-1727 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"60","span":{"begin":37,"end":45},"obj":"Species"},{"id":"61","span":{"begin":50,"end":58},"obj":"Species"},{"id":"62","span":{"begin":140,"end":145},"obj":"Species"},{"id":"63","span":{"begin":146,"end":150},"obj":"Species"}],"attributes":[{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:694009"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:1335626"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:9606"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:11118"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"accine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S s"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":228,"end":235},"obj":"Body_part"},{"id":"T3","span":{"begin":278,"end":285},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"accine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S s"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T11","span":{"begin":37,"end":45},"obj":"Disease"}],"attributes":[{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"accine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S s"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T14","span":{"begin":140,"end":145},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"accine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S s"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T2","span":{"begin":228,"end":235},"obj":"Chemical"},{"id":"T3","span":{"begin":278,"end":285},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"accine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S s"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T31","span":{"begin":37,"end":45},"obj":"SP_10"},{"id":"T32","span":{"begin":50,"end":58},"obj":"SP_9"},{"id":"T33","span":{"begin":140,"end":145},"obj":"SP_6;NCBITaxon:9606"},{"id":"T34","span":{"begin":254,"end":260},"obj":"SO:0000417"},{"id":"T35","span":{"begin":276,"end":285},"obj":"PG_1"},{"id":"T48545","span":{"begin":37,"end":45},"obj":"SP_10"},{"id":"T62193","span":{"begin":50,"end":58},"obj":"SP_9"},{"id":"T56881","span":{"begin":140,"end":145},"obj":"SP_6;NCBITaxon:9606"},{"id":"T78790","span":{"begin":254,"end":260},"obj":"SO:0000417"},{"id":"T16061","span":{"begin":276,"end":285},"obj":"PG_1"}],"text":"accine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S s"}